



European  
Commission

# Europe's Beating Cancer Plan



## Diagnosis and treatment

**Start date – end date**  
01/03/2023 - 01/03/2025

**Countries**  
Austria, Belgium, France

**Overall budget**  
EUR 499 670

**EU contribution under  
EU4Health programme**  
EUR 299 800



## EUCAPA – European Capacity Building for Patients


Typically, a Health Technology Assessment (HTA) measures the added value of a new medicine in comparison with the best existing treatment. Patients have direct knowledge on which side effects are manageable, the impact and most relevant factors, and the qualitative meaning of quality-of-life improvements. EUCAPA will ensure that the HTA Cooperation includes the patient perspective.

The Regulation on Health Technology Assessments (HTA) EU2021/2282, which entered into force in January 2022 and applies from January 2025, has significantly increased the importance and role of patient experts in the HTA process. Specifically, patient experts will participate in two main areas of work: the joint clinical assessments for medicines and medical devices and joint scientific consultations. Patient organisations will provide input on horizontal and strategic issues through the Stakeholder Network and meetings with the Coordination Group.


EUCAPA will ensure that participating patients have everything they need through three types of training:

Specifically, it will:


- Knowledge and capacity to understand HTA goals, methods and processes, especially those developed by EUnetHTA21 for implementing the European HTA regulation.
- Necessary skills to enable competent participation in joint scientific consultations and joint clinical assessments, and to critically appraise HTA reports and communicate their results and conclusions.
- Ability to actively discuss the different stakeholder positions regarding implementation of HTA in decision making.



### EUCAPA will deliver the following:



- A **training programme for patients** participating in their individual capacity to joint scientific consultations and joint clinical assessments, which focuses on ensuring the independence and impartiality of patient experts involved in joint HTA work.
- Increased **awareness among patients and patient organisations** on the new HTA regulation and engagement at national and Union level.
- A list of **national and EU-wide patient organisations per disease area** who could support the joint work of Coordination Group in the framework set out by the HTA Regulation.
- A list of **candidate patient experts** trained by the national and/or EU-wide patient organisations, who could provide input to joint clinical assessments and joint scientific consultations as set out by the HTA Regulation.



#### For more info

#### Contact details

Julien Delaye  
EURORDIS  
[www.eurordis.org](http://www.eurordis.org)  
[eucapahta@gmail.com](mailto:eucapahta@gmail.com)

#### Project website

[www.eucapa.eu](http://www.eucapa.eu)

#### Social media handles

**in** @EU-CAPA  
**X** @EUCAPA4HTA



Europe's Beating Cancer Plan makes use of the whole range of Commission funding instruments with a total of €4 billion being earmarked for actions addressing cancer. €1.25 billion from the EU4Health programme is being used to support actions and initiatives outlined in the Cancer Plan.

© European Union, 2024

Reuse of this document is allowed, provided appropriate credit is given and any changes are indicated (Creative Commons Attribution 4.0 International license). For any use or reproduction of elements that are not owned by the EU, permission may need to be sought directly from the respective right holders. All images © Gettyimages